Bruce C. Cozadd - 18 Nov 2025 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
Director
Signature
By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd
Issuer symbol
JAZZ
Transactions as of
18 Nov 2025
Net transactions value
-$3,259,538
Form type
4
Filing time
20 Nov 2025, 20:03:29 UTC
Previous filing
03 Oct 2025
Next filing
01 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
COZADD BRUCE C Director 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, IRELAND By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd 20 Nov 2025 0001193210

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Sale $609,411 -3,384 -0.83% $180.09 405,442 18 Nov 2025 Direct F1
transaction JAZZ Ordinary Shares Sale $1,516,131 -8,382 -2.1% $180.88 397,060 18 Nov 2025 Direct F2
transaction JAZZ Ordinary Shares Sale $1,003,071 -5,517 -1.4% $181.81 391,543 18 Nov 2025 Direct F3
transaction JAZZ Ordinary Shares Sale $130,925 -717 -0.18% $182.60 390,826 18 Nov 2025 Direct F4
transaction JAZZ Ordinary Shares Award $0 +2,506 +0.64% $0.000000 393,332 20 Nov 2025 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $179.4013 to $180.38. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $180.4028 to $181.385. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $181.41 to $182.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4 Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $181.59 to $182.77. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5 These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026.